Skip to main content
Premium Trial:

Request an Annual Quote

Syapse Closes $30M Series D Round

CHICAGO (GenomeWeb) – Syapse, a maker of software to support precision oncology care, has raised $30 million in a Series D round of venture capital from a variety of investors.

Previous investors that participated in the new round include Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Safeguard Scientifics, and Social Capital. Also investing this time are Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund, and Roche Venture Fund.

San Francisco-based Syapse said it would use the cash infusion to step up sales and support for more hospitals, including community health systems. The company said this would help more eligible patients find and participate in relevant clinical trials.

"Targeted therapeutics and precision diagnostics have been shown to save lives and lower the cost of care, but without tools like Syapse, they've been inaccessible to the community oncologists that represent 70 percent of patient care," John Kuelper, investment director at Ascension Ventures, said in a statement. "Syapse empowers physicians to collaborate with each other and the broader medical ecosystem, ensuring that these breakthrough technologies are available to the patients who need them."

Syapse last announced a fundraise in early 2016, when it closed on a $25 million Series C round.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.